Author Correction: Gut microbiome structure and metabolic activity in inflammatory bowel disease (Nature Microbiology, (2019), 4, 2, (293-305), 10.1038/s41564-018-0306-4);Gut microbiome structure and metabolic activity in inflammatory bowel disease

Nature Microbiology

Volumn 4, Issue 2, 2019, Pages 293-305

  Franzosa, Eric A ^a,b   Sirota Madi, Alexandra ^a   Avila Pacheco, Julian ^a   Fornelos, Nadine ^a   Haiser, Henry J ^c   Reinker, Stefan ^c   Vatanen, Tommi ^a   Hall, A Brantley ^a   Mallick, Himel ^a,b   McIver, Lauren J ^a,b   Sauk, Jenny S ^d   Wilson, Robin G ^d   Stevens, Betsy W ^d   Scott, Justin M ^a   Pierce, Kerry ^a   Deik, Amy A ^a   Bullock, Kevin ^a   Imhann, Floris ^e   Porter, Jeffrey A ^f   Zhernakova, Alexandra ^e   Fu, Jingyuan ^e   Weersma, Rinse K ^e   Wijmenga, Cisca ^e,g   Clish, Clary B ^a   Vlamakis, Hera ^a   Huttenhower, Curtis ^a,b   Xavier, Ramnik J ^a,d,h   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF OSLO   (Norway)

^h Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CALGRANULIN; SPHINGOLIPID; TETRAPYRROLE DERIVATIVE; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADAPTATION; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; FECES ANALYSIS; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOME; METABOLOMICS; METAGENOME; METAGENOMICS; MICROBIAL METABOLISM; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; ULCERATIVE COLITIS; VALIDATION STUDY; BIODIVERSITY; CHEMISTRY; COMPARATIVE STUDY; FECES; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MICROBIOLOGY;

BIODIVERSITY; BIOMARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; FECES; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; METABOLOME; METAGENOME;

EID: 85058195128     PISSN: None     EISSN: 20585276     Source Type: Journal    
DOI: 10.1038/s41564-019-0442-5     Document Type: Erratum

References (58)

1. Wlodarska, M., Kostic, A. D. & Xavier, R. J. An integrative view of microbiome-host interactions in inflammatory bowel diseases. Cell Host Microbe 17, 577–591 (2015)
2. Imhann, F. et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 67, 108–119 (2018)
3. Huttenhower, C., Kostic, A. D. & Xavier, R. J. Inflammatory bowel disease as a model for translating the microbiome. Immunity 40, 843–854 (2014)
4. Morgan, X. C. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 13, R79 (2012)
5. Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15, 382–392 (2014)
6. Haberman, Y. et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J. Clin. Invest. 124, 3617–3633 (2014)
7. Lane, E. R., Zisman, T. L. & Suskind, D. L. The microbiota in inflammatory bowel disease: current and therapeutic insights. J. Inflamm. Res. 10, 63–73 (2017)
8. Blander, J. M., Longman, R. S., Iliev, I. D., Sonnenberg, G. F. & Artis, D. Regulation of inflammation by microbiota interactions with the host. Nat. Immunol. 18, 851–860 (2017)
9. Dorrestein, P. C., Mazmanian, S. K. & Knight, R. Finding the missing links among metabolites, microbes, and the host. Immunity 40, 824–832 (2014)
10. McHardy, I. H. et al. Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships. Microbiome 1, 17 (2013)
11. Wu, G. D. Diet, the gut microbiome and the metabolome in IBD. Nestle Nutr. Inst. Workshop Ser. 79, 73–82 (2014)
12. Kim, S., Kim, J.-H., Park, B. O. & Kwak, Y. S. Perspectives on the therapeutic potential of short-chain fatty acid receptors. BMB Rep. 47, 173–178 (2014)
13. Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569–573 (2013)
14. Fernando, M. R., Saxena, A., Reyes, J.-L. & McKay, D. M. Butyrate enhances antibacterial effects while suppressing other features of alternative activation in IL-4-induced macrophages. Am. J. Physiol. Gastrointest. Liver Physiol. 310, G822–G831 (2016)
15. Marchesi, J. R. et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J. Proteome Res. 6, 546–551 (2007)
16. Wikoff, W. R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl Acad. Sci. USA 106, 3698–3703 (2009)
17. Williams, B. B. et al. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 16, 495–503 (2014)
18. Zelante, T. et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39, 372–385 (2013)
19. Lamas, B. et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med. 22, 598–605 (2016)
20. Le Gall, G. et al. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J. Proteome Res. 10, 4208–4218 (2011)
21. Bjerrum, J. T. et al. Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn’s disease and healthy individuals. Metabolomics 11, 122–133 (2015)
22. De Preter, V. et al. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. Gut 64, 447–458 (2015)
23. Jansson, J. et al. Metabolomics reveals metabolic biomarkers of Crohn’s disease. PLoS ONE 4, e6386 (2009)
24. Kolho, K.-L., Pessia, A., Jaakkola, T., de Vos, W. M. & Velagapudi, V. Faecal and serum metabolomics in paediatric inflammatory bowel disease. J. Crohns Colitis 11, 321–334 (2017)
25. Jacobs, J. P. et al. A disease-associated microbial and metabolomics state in relatives of pediatric inflammatory bowel disease patients. Cell. Mol. Gastroenterol. Hepatol. 2, 750–766 (2016)
26. Melnik, A. V. et al. Coupling targeted and untargeted mass spectrometry for metabolome-microbiome-wide association studies of human fecal samples. Anal. Chem. 89, 7549–7559 (2017)
27. Sokol, H. & Seksik, P. The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. Curr. Opin. Gastroenterol. 26, 327–331 (2010)
28. Joossens, M. et al. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut 60, 631–637 (2011)
29. Sokol, H. et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 15, 1183–1189 (2009)
30. Wishart, D. S. et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 35, D521–D526 (2007)
31. Mosli, M. H. et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am. J. Gastroenterol. 110, 802–819 (2015)
32. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300 (1995)
33. Duboc, H. et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 62, 531–539 (2013)
34. Abdel Hadi, L., Di Vito, C. & Riboni, L. Fostering inflammatory bowel disease: sphingolipid strategies to join forces. Mediators Inflamm. 2016, 3827684 (2016)
35. An, D. et al. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell 156, 123–133 (2014)
36. Braun, A. et al. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm. Bowel Dis. 15, 1705–1720 (2009)
37. Qi, Y. et al. PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate. Am. J. Physiol. Gastrointest. Liver Physiol. 307, G564–G573 (2014)
38. Fischbeck, A. et al. Sphingomyelin induces cathepsin D-mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis. Gut 60, 55–65 (2011)
39. Heimerl, S. et al. Alterations in intestinal fatty acid metabolism in inflammatory bowel disease. Biochim. Biophys. Acta 1762, 341–350 (2006)
40. Hove, H. & Mortensen, P. B. Influence of intestinal inflammation (IBD) and small and large bowel length on fecal short-chain fatty acids and lactate. Dig. Dis. Sci. 40, 1372–1380 (1995)
41. Stuart, J. M., Segal, E., Koller, D. & Kim, S. K. A gene-coexpression network for global discovery of conserved genetic modules. Science 302, 249–255 (2003)
42. Wolfe, C. J., Kohane, I. S. & Butte, A. J. Systematic survey reveals general applicability of” guilt-by-association” within gene coexpression networks. BMC Bioinformatics 6, 227 (2005)
43. Frank, D. N. et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 104, 13780–13785 (2007)
44. Lewis, J. D. et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. Cell Host Microbe 18, 489–500 (2015)
45. Desbois, A. P. & Smith, V. J. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. Appl. Microbiol. Biotechnol. 85, 1629–1642 (2010)
46. German, J. B. & Dillard, C. J. Saturated fats: a perspective from lactation and milk composition. Lipids 45, 915–923 (2010)
47. Galland, L. Magnesium and inflammatory bowel disease. Magnesium 7, 78–83 (1988)
48. Lih-Brody, L. et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig. Dis. Sci. 41, 2078–2086 (1996)
49. Yang, J. Y. et al. Molecular networking as a dereplication strategy. J. Nat. Prod. 76, 1686–1699 (2013)
50. Jaskowski, T. D., Litwin, C. M. & Hill, H. R. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease. Clin. Vaccine Immunol. 13, 655–660 (2006)
51. Tigchelaar, E. F. et al. Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics. BMJ Open 5, e006772 (2015)
52. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014)
53. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012)
54. Segata, N. et al. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat. Methods 9, 811–814 (2012)
55. Franzosa, E. et al. Species-level functional profiling of metagenomes and metatranscriptomes. Nat. Methods 15, 962–968 (2018)
56. Suzek, B. E. et al. UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches. Bioinformatics 31, 926–932 (2015)
57. Buchfink, B., Xie, C. & Huson, D. H. Fast and sensitive protein alignment using DIAMOND. Nat. Methods 12, 59–60 (2015)
58. The UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 45632, D158–D169 (2017)